Tango Therapeutics president sells $572k in shares

Adam Crystal, President R&D of Tango Therapeutics, sold 27,000 shares on April 1, 2026 for approximately $572,478 (prices $21.00–$21.69) and exercised options to acquire 27,000 shares at $5.20 ($140,400); he now directly owns 112,622 shares and trades were under a 10b5-1 plan. Tango reported a Q4 2025 net loss of $38.7M and a full-year loss of $101.6M, but analysts turned positive: Stifel kept a Buy and raised its price target to $24 from $15, Jefferies raised its PT to $18 from $14, and Mizuho initiated with an outperform and $19 PT. Analysts cite encouraging early data on PRMT5 and RAS(ON) combos and the vopimetostat program, supporting a constructive outlook despite the current losses.

Analysis

The market reaction and analyst momentum are disproportionately subsidizing optionality around the lead precision-oncology program rather than underlying cash dynamics. That creates a structure where near-term positive clinical readouts or partnership headlines can meaningfully re-rate the equity (stretching implied move multiples), while absent those catalysts the stock is exposed to dilution and trading desks’ hedging flows that can compress realized upside over 3–12 months.

A supply agreement with a specialized supplier materially shortens the path-to-combo commercialization by reducing manufacturing risk and shortening partner diligence timelines; second-order winners are CDMOs and mid‑cap oncology names positioned to participate in combination trials, while pure-play small PRMT5 developers without manufacturing partnerships face longer time-to-market and financing stress. Expect CRO enrollment velocity and batch-release milestones to show up as discrete micro-catalysts — each can move sentiment 15–30% intra-quarter for companies at this stage.

Tail risks are classic binary biotech: safety or lack-of-efficacy readouts and an accelerated cash runway that forces dilutive financing within 6–18 months. Conversely, a licensing deal or positive combo data within the next 6–12 months could produce asymmetric outcomes (3x+ on option structures) driven more by multiple expansion than by incremental revenue. Practical near-term hedges are therefore preferable to outright long exposure unless financed by selling front-month volatility that dealers are likely to bid aggressively ahead of binaries.

Key Decisions for Investors

• TNGX: Buy a calendar call spread to express asymmetric upside with controlled cash outlay — buy Jan-2028 calls ~1.25–1.75x OTM and sell Dec-2026 near-term calls to fund ~60–75% of the purchase. Position sizing 0.5% NAV; max loss = premium paid, upside 2.5–4x if positive readouts/partnership within 12–18 months.
• TNGX: If already long, sell 4–8 week covered calls at near-term strikes to harvest IV ahead of expected enrollment/milestone updates; use proceeds to buy 6–12 month protective puts (collar). Target reduction in effective cost basis by 20–40% of one-way downside exposure.
• ERAS: Establish a small directional long (1% NAV) with 12–18 month horizon to capture supplier rerating risk-premium should manufacturing become a gating item for combo trials. Stop-loss 25%; target 40–80% upside on re-rating/volume-led margin expansion.
• Hedged pair (event-driven): Long TNGX call spread (as above) financed by short near-term ERAS calls only if ERAS IV is rich — this expresses company-specific upside while monetizing immediate volatility in the supplier. Keep net delta neutral and cap allocation to 0.5–1% NAV to limit event-concentration risk.